Novome raises $33M series A, shoots for the gut with engineered microbes

Novome’s engineered microbe platform attracted DCVC Bio to lead its $33 million series A because of the potential it offers for a non-invasive mechanism to deliver biologics to the gut, a long-standing industry goal. The funds will provide enough runway for the biotech to take its lead candidate, an unnamed hyperoxaluria therapy, through Phase I testing.

The biotech also hired ex-Achaogen CEO Blake Wise as CEO Tuesday. ...